Patents by Inventor Didier J. Leturcq
Didier J. Leturcq has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9222070Abstract: T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCs; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen.Type: GrantFiled: July 24, 2007Date of Patent: December 29, 2015Assignee: Janssen Pharmaceuticals, Inc.Inventors: Didier J. Leturcq, Ann M. Moriarty, Michael R. Jackson, Per A. Peterson, Jon M. Richards
-
Patent number: 9222071Abstract: T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCs; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen.Type: GrantFiled: January 16, 2008Date of Patent: December 29, 2015Assignee: Janssen Pharmaceuticals, Inc.Inventors: Ann Moriarty, Didier J. Leturcq, Juli Degraw, Michael R. Jackson, Per A. Peterson, Marja Heiskala
-
Publication number: 20090004142Abstract: T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCs; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen.Type: ApplicationFiled: July 24, 2007Publication date: January 1, 2009Inventors: Didier J. Leturcq, Ann M. Moriarty, Michael R. Jackson, Per A. Peterson, Jon M. Richards
-
Patent number: 7326569Abstract: This invention provides hybridoma cell lines producing monoclonal antibodies which inhibit CD14 mediated cell activation. Monoclonal antibodies produced by these cell lines also are provided. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent disorders with CD14 mediated cell activation, such as sepsis.Type: GrantFiled: September 3, 2002Date of Patent: February 5, 2008Assignee: The Scripps Research InstituteInventors: Didier J. Leturcq, Ann M. Moriarty, Richard J. Ulevitch, Peter S. Tobias, John C. Mathison
-
Patent number: 6828150Abstract: The present invention relates to synthetic antigen-presenting matrices, their methods of making and their methods of use. One such matrix is cells that have been transfected to produce MHC antigen-presenting molecules and assisting molecules such as co-stimulatory molecules. The matrices can be used to activate CD8+ T-cells to produce cytokines and become cytotoxic.Type: GrantFiled: October 8, 2002Date of Patent: December 7, 2004Assignee: The Scripps Research InstituteInventors: Zeling Cai, Jonathan Sprent, Anders Brunmark, Michael Jackson, Per A. Peterson, Alain Luxembourg, Didier J. Leturcq, Ann M. Moriarty
-
Publication number: 20040071671Abstract: T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCS; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen.Type: ApplicationFiled: November 7, 2002Publication date: April 15, 2004Inventors: Didier J. Leturcq, Ann M. Moriarty, Michael R. Jackson, Per A. Peterson, Jon M. Richard
-
Publication number: 20030138946Abstract: The present invention relates to synthetic antigen-presenting matrices, their methods of making and their methods of use. One such matrix is cells that have been transfected to produce MHC antigen-presenting molecules and assisting molecules such as co-stimulatory molecules. The matrices can be used to activate CD8+ T-cells to produce cytokines and become cytotoxic.Type: ApplicationFiled: October 8, 2002Publication date: July 24, 2003Applicant: The Scripps Research InstituteInventors: Zeling Cai, Jonathan Sprent, Anders Brunmark, Michael Jackson, Per A. Peterson, Alain Luxembourg, Didier J. Leturcq, Ann M. Moriarty
-
Patent number: 6461867Abstract: Materials and methods of activating T lymphocytes with specificity for particular antigenic peptides are described, as well as the use of activated T lymphocytes in vitro for the treatment of a variety of disease conditions. In particular, a synthetic antigen presenting matrix for activating T lymphocytes to a specific peptide is described.Type: GrantFiled: September 8, 1997Date of Patent: October 8, 2002Assignee: The Scripps Research InstituteInventors: Zeling Cai, Jonathan Sprent, Anders Brunmark, Michael Jackson, Per A. Peterson, Alain Luxembourg, Didier J. Leturcq, Ann M. Moriarty
-
Patent number: 6444206Abstract: This invention provides hybridoma cell lines producing monoclonal antibodies which inhibit CD14 mediated cell activation. Monoclonal antibodies produced by these cell lines also are provided. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent disorders with CD14 mediated cell activation, such as sepsis.Type: GrantFiled: October 13, 1998Date of Patent: September 3, 2002Assignee: The Scripps Research InstituteInventors: Didier J. Leturcq, Ann M. Moriarty, Richard J. Ulevitch, Peter S. Tobias, John C. Mathison
-
Patent number: 5820858Abstract: This invention provides monoclonal antibodies that bind to the cell surface CD14 receptor and soluble CD14 receptor. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent LPS-associated disorders, such as sepsis.Type: GrantFiled: January 23, 1995Date of Patent: October 13, 1998Assignee: The Scripps Research InstituteInventors: Didier J. Leturcq, Ann M. Moriarty, Richard J. Ulevitch, Peter S. Tobias, John C. Mathison